Cargando…
Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial
Patients with glioblastoma (GBM) have a poor outcome, but even among patients receiving the same therapies and with good prognostic factors, one can find those with exceptionally short and long survival. From the Nordic trial, which randomized GBM patients of 60 years or older between two radiothera...
Autores principales: | Łysiak, Małgorzata, Das, Jyotirmoy, Malmström, Annika, Söderkvist, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452748/ https://www.ncbi.nlm.nih.gov/pubmed/36092918 http://dx.doi.org/10.3389/fgene.2022.934519 |
Ejemplares similares
-
Sex Disparities in MGMT Promoter Methylation and Survival in Glioblastoma: Further Evidence from Clinical Cohorts
por: Smits, Anja, et al.
Publicado: (2021) -
Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma
por: Malmström, Annika, et al.
Publicado: (2020) -
Deletions on Chromosome Y and Downregulation of the SRY Gene in Tumor Tissue Are Associated with Worse Survival of Glioblastoma Patients
por: Łysiak, Małgorzata, et al.
Publicado: (2021) -
TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma
por: Mosrati, Mohamed Ali, et al.
Publicado: (2015) -
The sex‐dependent role of the androgen receptor in glioblastoma: results of molecular analyses
por: Łysiak, Małgorzata, et al.
Publicado: (2022)